IP Library Granted Patent US 10,500,334
Granted Patent B2
US 10,500,334 · App. 15/870,666 · Granted Dec 10, 2019

System and method for adjusting insulin delivery

Inventors: Bryan Mazlish (Palo Alto, CA); Lane Desborough (Thousand Oaks, CA); Ross Naylor (Fullerton, CA)
Assignee: Bigfoot Biomedical, Inc.
A61M5/1723A61B5/14532A61B5/4839A61M5/14248A61M5/31568G16H20/17A61K38/28A61M5/003A61M2205/35A61M2205/502A61M2205/52A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,500,334
App. No.
15/870,666
Granted
Dec 10, 2019
Kind
B2
Abstract

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Some methods and systems may be configured to adjust insulin delivery to a person with diabetes according to one or more conditions of an insulin delivery device. Some methods and systems may be configured to enable a lock-out mode where adjustment to insulin delivery to personalize automated insulin delivery is restricted.

Claims (28)

1. A system, comprising:

an insulin delivery device configured to deliver insulin to a user of the insulin delivery device; and

an insulin delivery control unit associated with the insulin delivery device,

wherein the insulin delivery control unit is configured to:

determining a shelf-life risk score for undelivered insulin within the insulin delivery device; and

based on the shelf-life risk score exceeding a threshold, enabling a lock-out mode for locking out automated modification of a baseline basal insulin rate for the user of the insulin delivery device until the insulin delivery device has fresh insulin.

2. The system of claim 1 , wherein the shelf-life risk score is at least based on an age of the undelivered insulin.

3. The system of claim 1 , wherein determining a shelf-life risk score for undelivered insulin within the insulin delivery device comprises receiving a shelf-life risk score from a diabetes management system.

4. The system of claim 1 , wherein the insulin delivery control unit controls the insulin delivery device to:

deliver insulin at a first point in time according to a first insulin delivery action of a first series of insulin delivery actions of a first insulin delivery profile, the first series of insulin delivery actions including at least one action that includes delivering insulin at a rate larger than the baseline basal insulin rate; and

deliver insulin at a second point in time according to a first insulin delivery action of a second series of insulin delivery actions of a second insulin delivery profile, the second series of insulin delivery actions including delivering insulin at the rate larger than the baseline basal insulin rate,

wherein the shelf-life risk score is further based on a number of times insulin is delivered at the rate larger than the baseline basal insulin rate exceeding a threshold.

5. The system of claim 1 , further comprising a diabetes management system associated with the insulin delivery device and configured to track undelivered insulin within the insulin delivery device.

6. The system of claim 5 , wherein tracking undelivered insulin within the insulin delivery device comprises tracking an age of undelivered insulin.

7. The system of claim 5 , wherein the diabetes management system associated with the insulin delivery device is configured to track insulin delivery actions of the insulin delivery device.

8. The system of claim 7 , wherein the diabetes management system associated with the insulin delivery device is configured to determine a frequency of an insulin delivery action of the tracked insulin delivery actions, wherein the insulin delivery action comprises delivering a dose of insulin that exceeds a threshold.

9. The system of claim 8 , wherein the threshold is a multiple or a fraction of the baseline basal insulin rate.

10. A method comprising:

determining a shelf-life risk score for undelivered insulin within an insulin delivery device; and

based on the shelf-life risk score exceeding a threshold, locking out automated modification of a baseline basal insulin rate for a user of the insulin delivery device until the insulin delivery device has fresh insulin.

11. The method of claim 10 , wherein the shelf-life risk score is at least based on an age of the undelivered insulin.

12. The method of claim 10 , wherein determining the shelf-life risk score for undelivered insulin within the insulin delivery device comprises receiving a shelf-life risk score from a diabetes management system.

13. The method of claim 10 , further comprising:

delivering insulin at a first point in time according to a first insulin delivery action of a first series of insulin delivery actions of a first insulin delivery profile, the first series of insulin delivery actions including at least one action that includes delivering insulin at a rate larger than the baseline basal insulin rate; and

delivering insulin at a second point in time according to a first insulin delivery action of a second series of insulin delivery actions of a second insulin delivery profile, the second series of insulin delivery actions including delivering insulin at the rate larger than the baseline basal insulin rate;

wherein the shelf-life risk score is further based on a number of times insulin is delivered at the rate larger than the baseline basal insulin rate exceeding a threshold.

14. The method of claim 10 , wherein locking out automated modification of a baseline basal insulin rate prevents modification of the baseline basal insulin rate upwards while allowing automated modification of the baseline basal insulin rate downwards.

15. The method of claim 10 , further comprising generating a message that the shelf-life risk score has exceeded the threshold.

Assignments (16)
SECURITY INTEREST Recorded Jan 10, 2025
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069870/0519 →
SECURITY INTEREST Recorded Jan 10, 2025
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069870/0456 →
SECURITY INTEREST Recorded Sep 30, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069074/0001 →
SECURITY INTEREST Recorded Sep 30, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069073/0912 →
SECURITY INTEREST Recorded Sep 24, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069030/0104 →
SECURITY INTEREST Recorded Sep 24, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069030/0296 →
SECURITY INTEREST Recorded Sep 23, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069019/0142 →
SECURITY INTEREST Recorded Sep 23, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069019/0188 →
SECURITY INTEREST Recorded Sep 12, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 068948/0324 →
SECURITY INTEREST Recorded Sep 12, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 068948/0172 →
SECURITY AGREEMENT SUPPLEMENT Recorded Sep 7, 2023
From: INSULET CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 064840/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2023
From: BIGFOOT BIOMEDICAL, INC.
To: INSULET CORPORATION
Reel/Frame 062900/0001 →
RELEASE OF SECURITY INTEREST Recorded Feb 17, 2023
From: MADRYN FUND ADMINISTRATION, LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 062793/0316 →
SECURITY INTEREST Recorded Feb 10, 2023
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 062702/0145 →
SECURITY INTEREST Recorded Mar 12, 2021
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 055583/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2018
From: MAZLISH, BRYAN; DESBOROUGH, LANE; NAYLOR, ROSS
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 047104/0053 →
Cited By (2)
US 12,521,486 US 12,551,621